Results 21 to 30 of about 2,348 (179)

Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study

Acta Dermato-Venereologica, 2022
Sonidegib, a hedgehog pathway inhibitor, is indicated for treatment of locally advanced basal cell carcinoma, based on the results of the BOLT study. However, to date, no real-world study of sonidegib has been reported.
Florian Herms, Barouyr Baroudjian, Julie Delyon, Pauline Laly, Pauline Tetu, Celeste Lebbe, Nicole Basset-Seguin   +6 more
doaj   +3 more sources

A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma [PDF]

Journal of Skin Cancer, 2017
Objectives. Based on single-arm trial data (BOLT), sonidegib was approved in the US and EU to treat locally advanced basal cell carcinomas (BCCs) ineligible for curative surgery or radiotherapy.
Dawn Odom, Deirdre Mladsi, Molly Purser, James A. Kaye, Eirini Palaka, Alina Charter, Jo Annah Jensen, Dalila Sellami   +7 more
doaj   +2 more sources

Case Report: PTCH1 splice-site mutation and sonidegib treatment in Gorlin-Goltz syndrome: clinical insights from a family case study [PDF]

Frontiers in Medicine
Gorlin-Goltz syndrome (nevoid basal cell carcinoma syndrome) is a rare autosomal dominant tumor-predisposition disorder characterized by multiple basal cell carcinomas (BCCs), odontogenic keratocysts of the jaws, and variable systemic manifestations ...
Linli Liu, Heng Du, Neng Wang, Shuang Lv, Chunshui Yu, Lingli Deng   +5 more
doaj   +2 more sources

The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area

Dermatology and Therapy, 2023
Introduction Basal cell carcinoma (BCC) is the most common skin malignancy in Caucasians. Globally, about 20% of BCCs involve the periocular region. The treatment of periocular BCC may be very challenging because of its proximity to the intracranial ...
Alessia Villani, Gabriella Fabbrocini, Giuseppe Micali, Luigi Fornaro, Luca Potestio, Massimiliano Scalvenzi   +5 more
doaj   +2 more sources

Trichoscopy and LC-OCT findings in sonidegib-induced alopecia in patients with advanced basal cell carcinoma

Dermatology Reports
Sonidegib is a Hedgehog pathway inhibitor (HHIs) used as first-line systemic treatment for patients with advanced basal cell carcinoma (aBCC). Alopecia is reported as a frequent adverse event (AE), occurring in 49% of patients. Forty-five patients with
Irina Ciobotariu, Gerardo Palmisano, Giacomo Caldarola, Alfredo Piccerillo, Francesco Tassone, Simone Cappilli, Alessandro Di Stefani, Ketty Peris   +7 more
doaj   +4 more sources

Sonidegib efficacy and safety in ultra‐nonagenarian patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Camilla Brunello, Andrea Corio, Marco Zanette, Raffaele Dante Caposiena Caro, Iris Zalaudek, Nicola di Meo   +5 more
wiley   +3 more sources

Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis

Acta Neuropathologica Communications, 2019
Background Medulloblastoma (MB) is the most common malignant brain tumour in children but also rarely occur in adults. Sonic Hedgehog (SHH) driven MB is associated with aberrant activation of the SHH signalling pathway.
Yuchen Li, Qingkun Song, Bryan W. Day
doaj   +2 more sources

Alcian blue‐positive stromal phenotype in basal cell carcinoma is associated with progression on first‐line hedgehog inhibitors [PDF]

The Journal of Pathology: Clinical Research
Basal cell carcinoma (BCC) is the most frequent malignancy in fair‐skinned populations. Although curable in most cases, approximately 4% of patients develop locally advanced or metastatic disease (advBCC) requiring systemic therapy.
Viola K DeTemple, Rudolf Stadler, Sabine Bredemeier, Sungyoung Chung, Katrin Schaper‐Gerhardt, Mareike Alter, Yenny Angela, Henner Stege, Ulrike Leiter, Jan Ohletz, Elisabeth Livingstone, Imke vonWasielewski, Jessica C Hassel, Julia Huynh, Christoffer Gebhardt, Claudia Pföhler, Ralf Gutzmer, Christina H Scheel   +17 more
doaj   +2 more sources

Locally advanced basal cell carcinoma: Real-life data with sonidegib [PDF]

, 2022
In recent years, the category of hedgehog pathway inhibitor (HHI) has shown great results in patients with advanced basal cell carcinoma (aBCC), but few real-life data on efficacy and safety profile of sonidegib are available. We report our management of
Zelin, Enrico, Conforti, Claudio, Vezzoni, Roberta, Toffoli, Ludovica, Zalaudek, Iris, Agozzino, Marina, di Meo, Nicola   +6 more
core   +1 more source

Mohs Surgery Outcomes for Basal Cell Carcinoma Treated With Neoadjuvant Sonic Hedgehog Inhibitor. [PDF]

Int J Dermatol
International Journal of Dermatology, Volume 65, Issue 7, Page 1493-1494, July 2026.
Barnawi G, Lazarowitz R, Aly S, Nukaly H, Weiss E.   +4 more
europepmc   +2 more sources